U.S. Markets closed

Results of the votes of the Combined Shareholders’ Meeting of April 16, 2021

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·8 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.


Daix (France), April 19, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the results of the votes of its Combined Shareholders’ Meeting on April 16, 2021.

The Combined Shareholders' Meeting was held under the chairmanship of Mr. Frédéric Cren, Chairman and Chief Executive Officer and cofounder of Inventiva, at the Company's registered office, 50, rue de Dijon - 21121 Daix, France, virtually, without the physical presence of the shareholders and other persons entitled to attend, in accordance with the derogatory measures relating to the adaptation of the rules of meeting and deliberation of shareholders' meetings taken by the French authorities because of the COVID-19 pandemic.

All the resolutions submitted to vote have been adopted by the shareholders, with the exception of the 24th resolution which would have empowered the Board of Directors to decide on share capital increases reserved for members of a company savings plan to be set up by the Company.

Pursuant to Article R. 22-10-14 IV. of the French Commercial Code, the Combined Shareholders’ Meeting approved, without modification, the compensation policy for corporate officers as presented in the 2020 Universal Registration Document (Part 3.5.1, pages 141 and seq.).

Information on the results of the votes is detailed below:

  • Total number of shares composing the share capital: 38 630 261

  • Total number of shares with voting rights: 38 585 566





Ordinary part

Extraordinary part

Shareholders

Shares

Votes

Shareholders

Shares

Votes

Shareholders present

0

0

0

0

0

0

Proxy to third parties

0

0

0

0

0

0

Proxy to the Chairman

221

2 652 173

2 673 283

221

2 652 173

2 673 283

Mail votes

113

27 197 719

38 630 397

113

27 197 719

38 630 397

TOTAL

334

29 849 892

41 303 680

334

29 849 892

41 303 680

Quorum

77.36%

77.36%


Resolutions

State of adoption

Number of represented shares

Proportion of represented share capital
(%)

Total number of votes cast

For

Against

Abstention

Number of votes

in % of votes cast

Number of votes

in % of votes cast

Number of votes

in % of the total voting rights

Resolution 1 - OGM

Adopted

29 849 892

77.27%

41 303 315

41 303 183

>99.99%

132

0.00%

365

0.00%

Resolution 2 - OGM

Adopted

29 849 892

77.27%

41 303 358

41 303 183

>99.99%

175

0.00%

322

0.00%

Resolution 3 - OGM

Adopted

29 849 892

77.27%

41 303 352

41 303 190

>99.99%

162

0.00%

328

0.00%

Resolution 4 - OGM

Adopted

29 849 892

77.27%

41 303 175

41 303 043

>99.99%

132

0.00%

505

0.00%

Resolution 5 - OGM

Adopted

29 849 892

77.27%

41 300 747

39 439 449

95.49%

1 861 298

4.51%

2 933

0.01%

Resolution 6 - OGM

Adopted

29 849 892

77.27%

41 300 730

39 439 383

95.49%

1 861 347

4.51%

2 950

0.01%

Resolution 7 - OGM

Adopted

29 849 892

77.27%

41 300 788

41 103 691

99.52%

197 097

0.48%

2 892

0.01%

Resolution 8 - OGM

Adopted

29 849 892

77.27%

41 301 840

40 440 278

97.91%

861 562

2.09%

1 840

0.00%

Resolution 9 - OGM

Adopted

29 849 892

77.27%

41 301 840

40 440 324

97.91%

861 516

2.09%

1 840

0.00%

Resolution 10 - OGM

Adopted

29 849 892

77.27%

41 301 990

41 292 738

99.98%

9 252

0.02%

1 690

0.00%

Resolution 11 - OGM

Adopted

29 849 892

77.27%

41 302 851

41 302 429

>99.99%

422

0.00%

829

0.00%

Resolution 12 - OGM

Adopted

29 849 892

77.27%

41 302 820

41 302 530

>99.99%

290

0.00%

860

0.00%

Resolution 13 - OGM

Adopted

29 849 892

77.27%

41 302 783

41 302 543

>99.99%

240

0.00%

897

0.00%

Resolution 14 - OGM

Adopted

29 849 892

77.27%

41 303 308

39 435 344

95.48%

1 867 964

4.52%

372

0.00%

Resolution 15 - EGM

Adopted

29 849 892

77.27%

41 302 548

41 105 591

99.52%

196 957

0.48%

1 132

0.00%

Resolution 16 - EGM

Adopted

29 849 892

77.27%

41 302 502

39 440 822

95.49%

1 861 680

4.51%

1 178

0.00%

Resolution 17 - EGM

Adopted

29 849 892

77.27%

41 302 552

39 437 788

95.49%

1 864 764

4.51%

1 128

0.00%

Resolution 18 - EGM

Adopted

29 849 892

77.27%

41 249 716

39 384 922

95.48%

1 864 794

4.52%

53 964

0.11%

Resolution 19 - EGM

Adopted

29 849 892

77.27%

41 249 666

39 385 456

95.48%

1 864 210

4.52%

54 014

0.11%

Resolution 20 - EGM

Adopted

29 849 892

77.27%

41 249 686

39 485 599

95.72%

1 764 087

4.28%

53 994

0.11%

Resolution 21 - EGM

Adopted

29 849 892

77.27%

41 249 644

39 386 420

95.48%

1 863 224

4.52%

54 036

0.11%

Resolution 22 - EGM

Adopted

29 849 892

77.27%

41 302 480

39 440 265

95.49%

1 862 215

4.51%

1 200

0.00%

Resolution 23 - EGM

Adopted

29 849 892

77.27%

41 302 584

39 432 702

95.47%

1 869 882

4.53%

1 096

0.00%

Resolution 24 - EGM

Rejected

29 849 892

77.27%

41 298 555

14 132 290

34.22%

27 166 265

65.78%

5 125

0.01%

Resolution 25 - EGM

Adopted

29 849 892

77.27%

41 298 575

41 297 126

>99.99%

1 449

0.00%

5 105

0.01%

Resolution 26 - EGM

Adopted

29 849 892

77.27%

41 297 529

39 436 321

95.49%

1 861 208

4.51%

6 151

0.01%

Resolution 27 - EGM

Adopted

29 849 892

77.27%

41 301 251

39 439 037

95.49%

1 862 214

4.51%

2 429

0.00%

Resolution 28 - EGM

Adopted

29 849 892

77.27%

41 298 590

39 435 399

95.49%

1 863 191

4.51%

5 090

0.01%

Resolution 29 - OGM

Adopted

29 849 892

77.27%

41 302 445

41 301 162

>99.99%

1 283

0.00%

1 235

0.00%


About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.

Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.

Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. In 2020, Inventiva announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH.

Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. Inventiva announced positive topline data from its Phase IIa clinical trial evaluating odiparcil for the treatment of adult MPS VI patients at the end of 2019 and received FDA Fast Track designation in MPS VI for odiparcil in October 2020.

In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration.

The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com

Contacts

Inventiva
Frédéric Cren
Chairman & CEO
info@inventivapharma.com
+33 3 80 44 75 00

Brunswick Group
Yannick Tetzlaff / Tristan Roquet Montegon /
Aude Lepreux
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

Westwicke, an ICR Company
Patricia L. Bank
Investor relations
patti.bank@westwicke.com
+1 415 513 1284


Attachment